Apr 21, 2010 - Data Suggest HDAC Inhibitors, Such as Belinostat, May Be Efficacious in the Treatment of Small Cell Lung Cancer - Results Indicate Synergy With Conventional Chemotherapy Agents - Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, announced results of a pre-clinical study conducted by the National Cancer Institute of belinostat in the treatment of small-cell lung cancer that was presented in a poster session on Wednesday, April 21, 2010 at the 101st Annual Meeting of the American Association for Cancer Research (AACR), being held at the Walter E. Washington Convention Center in Washington, DC."Based on the data presented today at AACR, we believe belinostat may be an effective treatment option for small-cell lung cancer,"... Spectrum Pharmaceuticals' Press Release -
